Linagliptin: all 129 studies that test it

Page 1 of 2. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.

• Metformin, Empagliflozin With Sitagliptin vs Linagliptin in Type 2 DiabetesEnrolling by invitationNCT07452913Phase 4
• Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin CombinationRecruitingNCT06862739Phase 4
• The Bioequivalence Study of Linagliptin 5 mg Film-coated Tablet in Healthy Thai VolunteersNot yet recruitingNCT06243809Phase 1
• This Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate PillsCompletedNCT03629054Phase 1Results posted
• Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TMCompletedNCT03429543Phase 3Results posted
• A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)TerminatedNCT03337698Phase 1/2Results posted
• A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)TerminatedNCT03281369Phase 1/2Results posted
• This Study Tests Whether Taking the Medicines Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills. The Study is Done in Healthy Men and Women and Measures the Amount of Each Medicine in the BloodCompletedNCT03259490Phase 1Results posted
• Linagliptin Add-on to Insulin Background TherapyCompletedNCT02897349Phase 3Results posted
• Empa/Lina FDC Food Effect Study (Japan)CompletedNCT02815644Phase 1Results posted
• Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Linagliptin Compared With the Free Combination of Empagliflozin Tablet and Linagliptin Tablet in Healthy Male and Female SubjectsCompletedNCT02758171Phase 1Results posted
• Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose ManagementCompletedNCT02608177Not applicableResults posted
• Linagliptin's Effect on CD34+ Stem CellsCompletedNCT02467478Phase 4Results posted
• The Effect of LINAGLIPTIN on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes SubjectsCompletedNCT02372630Phase 4Results posted
• Effects of Linagliptin on Endothelial FunctionCompletedNCT02350478Phase 4Results posted
• Linagliptin as Add on to Basal Insulin in the ElderlyCompletedNCT02240680Phase 4Results posted
• Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/750mg) Extended Release in Healthy SubjectsCompletedNCT02121509Phase 1Results posted
• Bioequivalence of a FDC Tablet of Linagliptin/Metformin (5mg/1000mg) Extended Release in Healthy SubjectsCompletedNCT02084082Phase 1Results posted
• Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/1000mg) Extended Release in Healthy Subjects.CompletedNCT02084056Phase 1Results posted
• ADA Linagliptin in Long Term CareCompletedNCT02061969Phase 4Results posted
• Linagliptin Inpatient TrialCompletedNCT02004366Phase 4Results posted
• The Effect of Linagliptin on Mitochondrial and Endothelial FunctionCompletedNCT01969084Phase 4Results posted
• Two-way Crossover Study in Healthy Male and Female Subjects to Evaluate the Bioequivalence of Jentadueto®.CompletedNCT01947153Phase 1Results posted
• Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)CompletedNCT01897532Phase 4Results posted
• Relative Bioavailability of 2 Fixed Dose Combinations of Linagliptin/Metformin Compared With Single TabletsCompletedNCT01845077Phase 1Results posted
• MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptinCompletedNCT01792518Phase 3Results posted
• Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 DiabetesCompletedNCT01778049Phase 3Results posted
• Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 DiabetesCompletedNCT01734785Phase 3Results posted
• Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 PatientsCompletedNCT01708902Phase 3Results posted
• Trial to Assess the Influence of 4 Weeks' Treatment With Linagliptin as Compared to Glimepiride and Placebo on Endothelial Function in Patients With Type 2 Diabetes Using FMD (Flow-Mediated Vasodilation)CompletedNCT01703286Phase 1Results posted
• Bioequivalence of Metformin Under Fed Conditions After Administration of Linagliptin / Metformin Fixed Dose Combination Tablet and Single TabletsCompletedNCT01581931Phase 1Results posted
• Pharmacokinetics of Fixed Dose Combination (FDC) Tablets of Linagliptin /MetforminCompletedNCT01540487Phase 1Results posted
• Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic ControlCompletedNCT01438814Phase 4Results posted
• Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 DiabetesCompletedNCT01342484Phase 2Results posted
• Bioequivalence of a Fixed Dose Combination Tablet Linagliptin/Pioglitazone Compared With Its Mono-componentsCompletedNCT01276327Phase 1Results posted
• CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 DiabetesCompletedNCT01243424Phase 3Results posted
• Relative Bioavailability of Two Different Batches of a Linagliptin / Metformin Combination Tablet in Healthy VolunteersCompletedNCT01216397Phase 1Results posted
• Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin TherapyCompletedNCT01215097Phase 3Results posted
• Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug naïve or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic ControlCompletedNCT01214239Phase 3Results posted
• Comprehensive Add on Study in JapanCompletedNCT01204294Phase 3Results posted
• Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-studyCompletedNCT01194830Phase 3Results posted
• Rel. BA of Empagliflozin (BI 10773)/Linagliptin FDC Tbl, Comparison With Mono-components, With a Second FDC Tablet and Influence of FoodCompletedNCT01189201Phase 1Results posted
• 30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 WeeksCompletedNCT01183013Phase 3Results posted
• Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal ImpairmentCompletedNCT01087502Phase 3Results posted
• Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 DiabetesCompletedNCT01084005Phase 3Results posted
• Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With PioglitazoneCompletedNCT00996658Phase 3Results posted
• Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 DiabetesCompletedNCT00954447Phase 3Results posted
• Treatment of Type 2 Diabetes With Linagliptin 2.5 mg Bid + Metformin 500 or 1000 mg Bid and Metformin 1000 mg BidCompletedNCT00915772Phase 3Results posted
• Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea DrugCompletedNCT00819091Phase 3Results posted
• Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background InclusiveCompletedNCT00800683Phase 3Results posted
• Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial DesignCompletedNCT00798161Phase 3Results posted
• A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is InappropriateCompletedNCT00740051Phase 3Results posted
• The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic PatientsCompletedNCT00716092Phase 2Results posted
• Japanese P III vs Voglibose and PlaceboCompletedNCT00654381Phase 3Results posted
• Efficacy vs Placebo as Initial Combination Therapy With PioglitazoneCompletedNCT00641043Phase 3Results posted
• Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 DiabetesCompletedNCT00622284Phase 3Results posted
• Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic ControlCompletedNCT00621140Phase 3Results posted
• BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 DiabetesCompletedNCT00602472Phase 3Results posted
• Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 DiabetesCompletedNCT00601250Phase 3Results posted
• Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes PatientsCompletedNCT00328172Phase 2Results posted
• Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 DiabetesCompletedNCT00309608Phase 2Results posted
• Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCl25 mg/5 mg/1000 mg Extended Release Tablet Versus Trijardy® XR 25 mg/5 mg/1000 mg Extended- Release TabletsCompletedNCT07872358Phase 1
• Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCl 25 mg/5 mg/1000 mg Extended Release Tablet Versus Trijardy® XR 25 mg/5 mg/1000 mg Extended- Release TabletsCompletedNCT07691203Phase 1
• Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCL 25mg/5mg/1000mg Extended-Release Tablets Versus Trijardy® XR Extended Release Film Coated TabletsCompletedNCT07213895Phase 1
• Bioequivalence Study to Compare Empagliflozin + Linagliptin 25 mg/5 mg Film-coated Tablets Versus Glyxambi 25 mg/ 5 mg Film-coated TabletsCompletedNCT06932159Phase 1
• Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.CompletedNCT06851962Phase 4
• A Pharmacokinetic Study of DW6013 (FDC of Linagliptin and Metformin) in Healthy Adult Volunteers in Fed ConditionCompletedNCT05874180Phase 1
• A Pharmacokinetic Study of DW6013 (FDC of Linagliptin and Metformin) in Healthy Adult VolunteersCompletedNCT05874167Phase 1
• LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 DiabetesCompletedNCT05313529Not applicable
• Efficacy of Empagliflozin or Linagliptin as an Alternative to Metformin for Treatment of Polycystic Ovary SyndromeStatus unknownNCT05200793Phase 4
• Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19CompletedNCT04542213Phase 3
• Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19TerminatedNCT04371978Phase 3
• Effects of DPP4 Inhibition on COVID-19WithdrawnNCT04341935Phase 4
• Effect of Low Dose Combination of Linagliptin + Metformin to Prevent DiabetesStatus unknownNCT04134650Phase 3
• Effect of Empagliflozin + Linagliptin + Metformin + Lifestyle in Patients With PrediabetesStatus unknownNCT04131582Phase 3
• Effect of Linagliptin + Metformin on Patients Who do Not Achieve Normoglucemia With MetformineCompletedNCT04088461Phase 4
• Effect of Evogliptin on Albuminuria in Patients With Type 2 Diabetes and Renal InsufficiencyCompletedNCT03667300Phase 2
• Efficacy and Safety of Empagliflozin in NODATTerminatedNCT03642184Phase 4
• Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2)WithdrawnNCT03504566Phase 4
• Renal Actions of Combined Empagliflozin and LINagliptin in Type 2 diabetESStatus unknownNCT03433248Phase 4
• A Study of Adding Linagliptin to Control Glycemic Variability and HbA1c in Peritoneal Dialysis Patients With Type 2 Diabetes(PDPD) With Premixed Insulin TherapyStatus unknownNCT03320031Phase 4
• Safety and Efficiency of Linagliptin (Trajenta) in the Setting of Internal Medicine DepartmentStatus unknownNCT03051243Phase 3
• Effect of Linagliptin + Metformin vs Metformin Alone in Patients With PrediabetesCompletedNCT03004612Phase 4
• Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets(Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany)CompletedNCT02857946Phase 1
• Effects of Linagliptin on Left Ventricular Myocardial DYsfunction in Patients With Type 2 DiAbetes Mellitus and Concentric Left Ventricular GeometryCompletedNCT02851745Phase 3
• The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 InhibitorsCompletedNCT02792400Not applicable
• The Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Advanced Glycation End ProductsWithdrawnNCT02768220Phase 4
• Incretin Axis in Type 1 Diabetes MellitusStatus unknownNCT02725502Not applicable
• Linagliptin and Mesenchymal Stem Cells: A Pilot StudyCompletedNCT02442817Phase 4
• Effects of Linagliptin in Addition to Empagliflozin on Islet Cell PhysiologyCompletedNCT02401880Phase 4
• Effects of Linagliptin on Endothelial- , Renal-, and Retinal Function in Patients With Hypertension and AlbuminuriaCompletedNCT02376075Phase 3
• Effect of Linagliptin on TRL MetabolismStatus unknownNCT02280174Phase 4
• Bioequivalence of a 2.5 mg Linagliptin / 500 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 500 mg Tablets Administered Together in Healthy VolunteersCompletedNCT02221414Phase 1
• Bioequivalence of a Linagliptin / Metformin Fixed-dose Combination (FDC) Tablet Compared With Single Linagliptin and Metformin Tablets Administered Together in Healthy VolunteersCompletedNCT02221401Phase 1
• Bioequivalence of a 2.5 mg Linagliptin / 850 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 850 mg Tablets in Healthy VolunteersCompletedNCT02220647Phase 1
• the Pharmacokinetic Profiles of Linagliptin With DW1029MCompletedNCT02212782Phase 1
• The Effect of Multiple Oral Doses of BI 1356 BS on Pharmacokinetics, Safety and Tolerability of Multiple Oral Doses of Simvastatin and on the Pharmacokinetics of Its Metabolite Simvastatin Acid in Healthy Male VolunteersCompletedNCT02183623Phase 1
• Study to Evaluate the Effect of Multiple Doses of Rifampicin on the Multiple-dose Pharmacokinetics of Linagliptin in Healthy VolunteersCompletedNCT02183584Phase 1
• Pharmacokinetics of Single and Multiple Oral Doses of BI 1356 in Healthy Chinese VolunteersCompletedNCT02183532Phase 1
• Bioavailability of BI 1356 BS and Metformin After Co-administration Compared to the Bioavailability of BI 1356 BS Alone and Metformin Alone in Healthy Male VolunteersCompletedNCT02183506Phase 1

← Linagliptin overview